Genetic Modulators of Glaucoma
青光眼的遗传调节剂
基本信息
- 批准号:10361394
- 负责人:
- 金额:$ 37.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AgeAxonBlindnessCandidate Disease GeneCell DeathCellular AssayCessation of lifeChromosome 12ClinicalComputing MethodologiesDataDatabasesDiseaseFamilyFutureGenerationsGenesGeneticGenetic HeterogeneityGenomicsGlaucomaGoalsHealthHumanHuman GenomeInbred Strains RatsInbreedingInvestigationLaboratoriesLeadMethodsModelingMolecularMusOcular HypertensionOptic NerveOutcomeOutcome StudyPathway interactionsPatientsPhenotypePhysiologic Intraocular PressurePopulationPositioning AttributeProcessPublicationsQuantitative Trait LociRattusRecombinantsRegulationResearchResearch PersonnelRetinaRetinal Ganglion CellsRiskRisk FactorsRodentSystemTestingTherapeuticUnited States National Institutes of HealthValidationVisual FieldsWorkage relatedcell injurycellular targetingclinical subtypescohortdeep neural networkdensityendophenotypeexperiencegene productgenetic analysisgenome wide association studyhuman datahuman modellead candidatenerve damagenovelnovel therapeuticspreservationsuccesstargeted treatmenttherapeutic developmenttreatment strategy
项目摘要
Glaucoma is the leading cause of irreversible blindness in the world. While elevated intraocular pressure (IOP)
is a major risk factor, damage and death of retinal ganglion cells (RGCs) underlies visual field loss. However, a
thorough understanding of this disease is a major challenge because its genetic basis is heterogeneous and it
represents a family of age-related disorders resulting from intersecting gene-regulated pathophysiologic
networks. We propose to continue to use the BXD (C57BL/6 x DBA/2J) family of recombinant inbred (RI) lines
of mice as a genetic reference panel (GRP) and to combine our work with human genome wide association
studies (GWAS), to uncover and clarify the genetic heterogeneity that underlies optic nerve (ON) damage. We
have had recent success using this combined approach in the regulation of intraocular pressure (IOP). We are
very well positioned to take the next step and apply this approach to define cellular targets of RGC damage
and death. We propose to uncover phenotypic diversities of glaucoma-related ON damage and uncover
common underlying mechanisms that are shared with IOP modulation. Our long-term research goal is to
identify disease mechanisms and develop neuroprotective therapies to preserve retinal health in patients at
risk for glaucoma. Our overall objective is to identify novel gene products and related mechanisms that lead to
glaucomatous endophenotypes using multi-dimensional genetic analyses, cross-species comparisons (mouse,
rat and human) and validation using novel murine glaucoma models. Our central hypothesis is that molecular
processes leading to glaucoma associated-endophenotypes, such as elevated IOP and ON damage, are
shared across species, and that species comparisons can uncover common underlying mechanisms, and
efficient testing of targeted glaucoma therapeutics. In the current investigation, we perform a systematic
analysis of ON damage, and an additional species—rat. We will mine the extensive databases of IOP and ON
damage that we are generating for more than 70 BXD strains across five age cohorts with the goal of defining
new models of glaucoma. An overall strength of this proposal is the combination of cutting-edge systems
genetics methods, species comparisons of glaucoma phenotypes, and a strong interdisciplinary team that
includes investigators with extensive experience in systems genetics, glaucoma, GWAS in human and rats,
and advanced computational methods. To test our hypothesis, we will perform the following thress studies: 1)
Identify the candidate gene on chromosome 12 that modulates ON damage; 2) Determine if modulation of IOP
and/or ON damage is shared across rodent species; and 3) Identify novel spontaneous glaucoma models
through a comprehensive analysis of our enlarged BXD GRP of 100 or more BXD strains. The outcomes of
these studies will define novel genes and molecular networks that underlie glaucoma-associated phenotypes
and also provide unique glaucoma models for future analysis. These results are expected to fundamentally
advance the field of glaucoma disease mechanisms and enable targeted therapeutic development.
青光眼是世界上不可逆性失明的主要原因。当眼内压升高时,
是一个主要的危险因素,视网膜神经节细胞(RGC)的损伤和死亡是视野丧失的基础。但
彻底了解这种疾病是一个重大挑战,因为它的遗传基础是异质的,而且它
代表了由交叉基因调节的病理生理学引起的一系列与年龄相关的疾病
网络.我们建议继续使用BXD(C57 BL/6 x DBA/2 J)家族的重组近交(RI)系
作为遗传参考面板(GRP),并将我们的工作与人类全基因组关联联合收割机结合起来
研究(GWAS),以揭示和澄清视神经(ON)损伤的遗传异质性。我们
最近在眼内压(IOP)的调节中使用这种组合方法取得了成功。我们
非常适合采取下一步并应用这种方法来定义RGC损伤的细胞靶点
与死我们建议揭示与肿瘤相关的ON损伤的表型差异,
与IOP调节共有的共同潜在机制。我们的长期研究目标是
确定疾病机制并开发神经保护疗法以保护患者的视网膜健康,
青光眼的风险。我们的总体目标是确定新的基因产物和相关机制,导致
使用多维遗传分析、跨物种比较(小鼠,
大鼠和人),并使用新的鼠青光眼模型进行验证。我们的核心假设是,
导致青光眼相关内表型的过程,如IOP升高和ON损伤,
跨物种共享,物种比较可以揭示共同的潜在机制,
有效测试靶向青光眼治疗方法。在目前的调查中,我们进行了系统的
ON损伤分析以及额外的物种-大鼠。我们将挖掘IOP和ON的广泛数据库
我们在五个年龄组中对70多种BXD菌株产生的损害,目的是定义
青光眼的新模型这一建议的整体优势在于结合了尖端系统
遗传学方法,青光眼表型的物种比较,以及强大的跨学科团队,
包括在系统遗传学、青光眼、人类和大鼠GWAS方面具有丰富经验的研究人员,
先进的计算方法。为了验证我们的假设,我们将进行以下三项研究:1)
鉴定12号染色体上调节ON损伤的候选基因; 2)确定IOP的调节是否
和/或ON损伤在啮齿动物物种中共有;和3)鉴定新的自发性青光眼模型
通过我们对100个或更多BXD菌株的放大BXD GRP的综合分析。的成果
这些研究将确定新的基因和分子网络,这些基因和分子网络构成了脑胶质瘤相关表型的基础
并且还为将来的分析提供独特的青光眼模型。这些结果预计将从根本上
推进青光眼疾病机制领域的研究,实现靶向治疗开发。
项目成果
期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systems genetics identifies a role for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility.
- DOI:10.1038/s41467-017-00837-5
- 发表时间:2017-11-24
- 期刊:
- 影响因子:16.6
- 作者:Chintalapudi SR;Maria D;Di Wang X;Bailey JNC;NEIGHBORHOOD consortium;International Glaucoma Genetics consortium;Hysi PG;Wiggs JL;Williams RW;Jablonski MM
- 通讯作者:Jablonski MM
Genetic pathways regulating glutamate levels in retinal Müller cells.
- DOI:10.1007/s11064-010-0277-1
- 发表时间:2011-04
- 期刊:
- 影响因子:4.4
- 作者:Jablonski, Monica M.;Freeman, Natalie E.;Orr, William E.;Templeton, Justin P.;Lu, Lu;Williams, Robert W.;Geisert, Eldon E.
- 通讯作者:Geisert, Eldon E.
The social life of neurons: synaptic communication deficits as a common denominator of autism, schizophrenia, and other cognitive disorders.
- DOI:10.1016/j.biopsych.2012.05.013
- 发表时间:2012-08-01
- 期刊:
- 影响因子:10.6
- 作者:Heck, Detlef H.;Lu, Lu
- 通讯作者:Lu, Lu
A cross-species genetic analysis identifies candidate genes for mouse anxiety and human bipolar disorder.
- DOI:10.3389/fnbeh.2015.00171
- 发表时间:2015
- 期刊:
- 影响因子:3
- 作者:Ashbrook DG;Williams RW;Lu L;Hager R
- 通讯作者:Hager R
Genetic and immunohistochemical analysis of HSPA5 in mouse and human retinas.
小鼠和人类视网膜中 HSPA5 的遗传和免疫组织化学分析。
- DOI:
- 发表时间:2016
- 期刊:
- 影响因子:2.2
- 作者:Chintalapudi,SumanaR;Wang,XiaoFei;Li,Huiling;Lau,YinHChan;Williams,RobertW;Jablonski,MonicaM
- 通讯作者:Jablonski,MonicaM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MONICA M JABLONSKI其他文献
MONICA M JABLONSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MONICA M JABLONSKI', 18)}}的其他基金
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
9912475 - 财政年份:2020
- 资助金额:
$ 37.18万 - 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
10374760 - 财政年份:2020
- 资助金额:
$ 37.18万 - 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
10597097 - 财政年份:2020
- 资助金额:
$ 37.18万 - 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
- 批准号:
10542485 - 财政年份:2020
- 资助金额:
$ 37.18万 - 项目类别:
相似海外基金
An atypical microtubule generation mechanism for neurons drives dendrite and axon development and regeneration
神经元的非典型微管生成机制驱动树突和轴突的发育和再生
- 批准号:
23K21316 - 财政年份:2024
- 资助金额:
$ 37.18万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Characterizing Wnt Signaling Pathways in Axon Guidance
轴突引导中 Wnt 信号通路的特征
- 批准号:
10815443 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Does phosphorylation regulation of the axon initial segment cytoskeleton improve behavioral abnormalities in ADHD-like animal models?
轴突起始段细胞骨架的磷酸化调节是否可以改善 ADHD 样动物模型的行为异常?
- 批准号:
23KJ1485 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Collaborative Research: Evolution of ligand-dependent Robo receptor activation mechanisms for axon guidance
合作研究:用于轴突引导的配体依赖性 Robo 受体激活机制的进化
- 批准号:
2247939 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Standard Grant
Loss-of-function variants of the axon death protein SARM1 and protection from human neurodegenerative disease
轴突死亡蛋白 SARM1 的功能丧失变体和对人类神经退行性疾病的保护
- 批准号:
2891744 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Studentship
Understanding the degeneration of axon and nerve terminals in Alzheimer's disease and related dementia brain
了解阿尔茨海默病和相关痴呆大脑中轴突和神经末梢的变性
- 批准号:
10661457 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Unlocking BIN1 function in oligodendrocytes and support of axon integrity
解锁少突胶质细胞中的 BIN1 功能并支持轴突完整性
- 批准号:
10901005 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Regulation of ion channel clustering at the axon initial segment by palmitoylation
棕榈酰化对轴突起始段离子通道聚集的调节
- 批准号:
477701 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Operating Grants














{{item.name}}会员




